Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 2/20 | 0.62 |
| ▸ | HCRTR1 | O43613 | 7/20 | 0.45 |
| ▸ | HCRTR2 | O43614 | 7/20 | 0.45 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | MMP1 | P03956 | 1/20 | 0.42 |
| ▸ | MMP9 | P14780 | 1/20 | 0.42 |
| ▸ | MMP13 | P45452 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6624711 | 0.85 | CASP3 (0.63) | CASP3HCRTR1HCRTR2FKBP1AKDM4E | |
| SCHEMBL17323673 | 0.85 | CASP3 (0.62) | CASP3HCRTR1HCRTR2KDM4EALDH1A1 | |
| SCHEMBL16014995 | 0.80 | CASP3 (0.62) | CASP3HCRTR1HCRTR2FKBP1AKDM4E | |
| SCHEMBL16014994 | 0.80 | CASP3 (0.62) | CASP3HCRTR1HCRTR2FKBP1AKDM4E | |
| SCHEMBL16129184 | 0.80 | CASP3 (0.62) | CASP3HCRTR1HCRTR2FKBP1AKDM4E | |
| SCHEMBL7086061 | 0.79 | CASP3 (0.61) | CASP3KDM4EALDH1A1MEN1POLB | |
| SCHEMBL7086065 | 0.79 | CASP3 (0.61) | CASP3KDM4EALDH1A1MEN1POLB | |
| SCHEMBL8248205 | 0.77 | CASP3 (0.59) | CASP3FKBP1AKDM4EALDH1A1MEN1 | |
| SCHEMBL6535374 | 0.77 | CASP3 (1.00) | CASP3 | |
| SCHEMBL6535370 | 0.77 | CASP3 (1.00) | CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250319046-A1 | PHENYLALANINE-BASED LAT1 INHIBITORS AND USES THEREOF | MAXYMUNE THERAPEUTICS INC (US) | 2025-10-16 | — | — | US | disclosed |
| US-12427124-B1 | Phenylalanine-based LAT1 inhibitors and uses thereof | Maxymune Therapeutics, Inc. (US) | 2025-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12427124-B1 | Phenylalanine-based LAT1 inhibitors and uses thereof | SLC43A1, SLC7A1, SLC1A5 | CASP3 4822/4885HCRTR1 3139/4885HCRTR2 2910/4885 |
| US-20250319046-A1 | PHENYLALANINE-BASED LAT1 INHIBITORS AND USES THEREOF | SLC43A1, SLC7A1, SLC1A5 | CASP3 4822/4885HCRTR1 3139/4885HCRTR2 2910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.